Contract development and manufacturing organisation (CDMO) Recipharm has delivered its first batch of serialised drug products to Saudi Arabia, following the introduction of new regulatory requirements in March 2017.
The €300,000 project, which is operating in addition to a wider €40 million investment into new serialisation technology and processes to comply with the European Falsified Medicines Directive, enables Recipharm to supply serialised products to Saudi Arabia.
Since the Saudi Food and Drug Authority enforced the latest version of the Saudi Drug Code, which aims to protect against counterfeit pharmaceuticals, Recipharm has serialised, packed, QP released and shipped more than 240,000 units to this market from its facility in Lisbon, Portugal. This includes three different stock keeping units (SKUs) and drug formulations including tablets to treat nausea and discomfort caused by gastroparesis and powder and tincture for skin infections.
Recipharm already supplies serialised products in several markets including Turkey, Korea and China.
Staffan Widengren, director corporate projects at Recipharm and the CDMO’s company-wide serialisation project lead, said: “Our investment in the Saudi Arabian market is the latest step in our goal to assist pharmaceutical companies with the complex web of requirements in the US, Europe and Asia.”
The CDMO has facilities in more than 20 locations across the globe and plans for a further six in the UK, Germany, Sweden, Spain and France to supply serialised products to Saudi Arabia according to customer requirements.